BeiGene (San Mateo, CA / Basel, CH) sponsors 87 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 36 active protocols (17 recruiting now), 43 completed protocols, and 6 all-time original FDA Drugs@FDA NDA and BLA approvals.